Fig. 3: Pleiotropic actions of mGlu3 receptors and potential relevance to the pathophysiology and treatment of PD. | npj Parkinson's Disease

Fig. 3: Pleiotropic actions of mGlu3 receptors and potential relevance to the pathophysiology and treatment of PD.

From: Targeting metabotropic glutamate receptors for symptomatic and disease-modifying treatment in Parkinson’s disease

Fig. 3

Presynaptic mGlu3 receptors are localized in the preterminal region of the axon terminal, and share with mGlu2 receptors the ability to inhibit glutamate release. This mechanism converges with the anti-inflammatory effect in microglia and the induction of TGF-β and GDNF in astrocytes to support the potential disease-modifying effect of mGlu3 receptor agonists or PAMs in PD. Postsynaptic mGlu3 receptors functionally interact with mGlu5 receptors, a mechanism implicated in the potential pro-cognitive effects of mGlu3 receptor agonists or PAMs. For simplicity, mGlu3 receptors are illustrated as monomers.

Back to article page